Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

ACTINOGEN MEDICAL LIMITED

INVESTOR PRESENTATION - ACTINOGEN MEDICAL LIMITED

ASX:ACW

ACTINOGEN MEDICAL LIMITED

Health Care

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

Read more

Market Cap

24.56m

Price at Close

$0.022

4w avg. Volume

3.74m

4w avg. Turnover

$91.97k

Announcements
announcementt+2 movementdate
  • Cleansing Notice

    Issued Capital

  • -

    22 Oct 2020

-

22 Oct 2020
  • Appendix 2A

    Issued Capital

  • -

    22 Oct 2020

-

22 Oct 2020
  • Change to Date of Annual General Meeting

    Notice Of Meeting

  • -8.00%

    16 Oct 2020

-8.00%

16 Oct 2020
  • Letter to Optionholders re Non-Renounceable Rights Issue

    Issued Capital

  • 0.00%

    15 Oct 2020

0.00%

15 Oct 2020
  • Notice under Section 708AA of the Corporations Act 2001 (Cth

    Issued Capital

  • -10.71%

    14 Oct 2020

-10.71%

14 Oct 2020
  • Actinogen Presentation & Planned Conference Call

    Periodic Reports · Market sensitive

  • -10.71%

    14 Oct 2020

-10.71%

14 Oct 2020
  • Proposed issue of Securities - ACW

    Issued Capital · Market sensitive

  • -10.71%

    14 Oct 2020

-10.71%

14 Oct 2020
  • ACW announces two clinical trials & launches capital raising

    Issued Capital · Market sensitive

  • -10.71%

    14 Oct 2020

-10.71%

14 Oct 2020
  • Trading Halt

    Stock Exchange Announcement · Market sensitive

  • 0.00%

    12 Oct 2020

0.00%

12 Oct 2020
  • Appendix 3G

    Issued Capital

  • +3.57%

    01 Oct 2020

+3.57%

01 Oct 2020
Market Data

Current Price

$0.022

52WK HIGH

$0.056

52WK LOW

$0.015

1YR RETURN

-48.84%

1YR RETURN VS. SECTOR

-72.29%

90 DAY RETURN

-4.35%

ASX RANK

1,368

/2,010

SECTOR RANK

36

/47

SHARES OUTSTANDING

1.12b
ASX:ACW

ACTINOGEN MEDICAL LIMITED

Health Care

Actinogen Medical is an ASX-listed biotechnology company developing innovative treatments for Alzheimer’s disease and the cognitive decline associated with neurodegenerative diseases and metabolic diseases, like Type 2 diabetes. Our management team and scientific advisory board includes world-renowned Alzheimer’s disease and dementia researchers, and industry specialists in drug design and clinical trial management. Actinogen Medical’s drug candidate Xanamem has been specifically designed to block the production of cortisol in the brain. Drugs that reduce cortisol in the brain offer a promising new approach to slowing, or even preventing, the cognitive decline associated with Alzheimer’s disease. Actinogen Medical has completed enrolment into XanADu, an international multi-site Phase II efficacy and safety trial of Xanamem in patients with mild Alzheimer’s disease. Recruitment and treatment of patients started in 2017, with results expected in Q2 CY19.

Read more

Market Cap

24.56m

Price at Close

$0.022

4w avg. Volume

3.74m

4w avg. Turnover

$91.97k

ASX:ACW is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.